1-5 of 5
Gavin S. Choy, PharmD
Close
Sort by
Journal Articles

Final Results of Anagrelide Controlled-Release (GALE-401) Safety, Efficacy and Pharmacokinetics in Subjects with Myeloproliferative Neoplasms (MPN)-Related Thrombocytosis

Phu V. Troung, MD F.A.C.P., Marc Saltzman, MD, Alberto Bessudo, MD, William Jawien, MD, Roger M. Lyons, MD F.A.C.P., Dmitriy Berenzon, MD, Raul Mena, MD, Nasiema Wingate-Pearse, Olivier Barriere, PhD, Hali E. Beeson, Paul F. Glidden, PhD, Gavin S. Choy, PharmD, MBA, Srdan Verstovsek, MD PhD
Journal: Blood
Blood (2015) 126 (23): 4074.
https://doi.org/10.1182/blood.V126.23.4074.4074
Published: 2015
Journal Articles

Targeting Pim Kinase Activity with the Novel Small Molecule Inhibitor SGI-1776 Significantly Augments the Efficacy of Cytarabine In Models of Acute Myeloid Leukemia

Kevin R Kelly, MD, Kelli Oberheu, B.S., Ernest Medina, B.S., Claudia M Espitia, MS, Devalingam Mahalingam, MD, PhD, Pietro Taverna, PhD, Gavin S. Choy, PharmD, MBA, Steffan T Nawrocki, PhD, Francis J. Giles, MB, MD, FRCPI, FRCPath, Jennifer S Carew, PhD
Journal: Blood
Blood (2010) 116 (21): 3253.
https://doi.org/10.1182/blood.V116.21.3253.3253
Published: 2010
Journal Articles

SGI-110, a Novel Second Generation Potent DNA Methylation Inhibitor, In Development for the Treatment of MDS and AML. Preclinical Safety, Pharmacokinetics, and DNA Methylation Results of a Low Volume Subcutaneous (SC) Formulation

Jason Scholl, PhD, Rajashree Joshi-Hangal, PhD, Roger Inloes, PhD, Chongtie Shi, PhD, Pietro Taverna, PhD, Gavin S. Choy, PharmD, MBA, Sanjeev Redkar, PhD, Mohammad Azab, MD, MSC, MBA
Journal: Blood
Blood (2010) 116 (21): 1872.
https://doi.org/10.1182/blood.V116.21.1872.1872
Published: 2010
Journal Articles

Marqibo (Vincristine Sulfate Liposomes Injection (OPTISOME™) Demonstrates Activity in Patients with Relapsed and Refractory Peripheral T-Cell Lymphoma.

M. Alma Rodriguez, MD, Jane N. Winter, MD, Biao Lu, PhD, Gary Huang, MD, Gavin S. Choy, PharmD, Steven R. Deitcher, MD
Journal: Blood
Blood (2007) 110 (11): 4466.
https://doi.org/10.1182/blood.V110.11.4466.4466
Published: 2007
Journal Articles

A Phase I Study of Talvesta® (Talotrexin) in Relapsed or Refractory Leukemia or Myelodysplastic Syndrome.

Francis Giles, MD, David A. Rizzieri, MD, Solly George, RN, Wendy Stock, MD, Jeannie Fontanilla, BS, Gavin S. Choy, PharmD, Gregory I. Berk, MD
Journal: Blood
Blood (2006) 108 (11): 1968.
https://doi.org/10.1182/blood.V108.11.1968.1968
Published: 2006